The Role of Vitamin D in Inflammatory Bowel Disease: Clinical Relevance and Therapeutic Potential

This narrative review examines what the current scientific literature tells us about vitamin D and inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis — two conditions marked by chronic, relapsing gut inflammation. The authors searched PubMed and Scopus for clinical studies, meta-analyses, systematic reviews, and experimental data, then synthesized findings on how vitamin D status relates to disease activity and outcomes. A consistent pattern emerged: patients with IBD are much more likely than the general population to have low vitamin D levels, and those lower levels track with more active disease, higher levels of inflammatory markers like C-reactive protein and fecal calprotectin, and worse quality of life. Mechanistically, vitamin D appears to work on at least three fronts — dampening inappropriate immune responses, reinforcing the epithelial barrier that lines the gut, and influencing the composition of the gut microbiota. Evidence for supplementation is most encouraging in Crohn's disease patients who are already in remission, though the data across all IBD patients remain mixed. The authors conclude that checking and correcting vitamin D deficiency is a low-cost, modifiable strategy worth adding to standard IBD care, while calling for well-designed randomized controlled trials to nail down optimal doses and timing.

• Vitamin D deficiency is highly prevalent in IBD patients and correlates with increased disease activity scores, higher serum C-reactive protein, and elevated fecal calprotectin levels.
• Low serum 25(OH)D is associated with greater risk of disease relapse and poorer patient-reported quality of life in both Crohn's disease and ulcerative colitis.
• Vitamin D exerts immunomodulatory effects via regulation of T-cell responses, maintenance of epithelial tight-junction integrity, and modulation of gut microbiota composition.
• Vitamin D supplementation shows the most consistent benefit in Crohn's disease patients in remission, though findings across the broader IBD population are heterogeneous and no universal optimal dosing strategy has been established.

This is a narrative review; no primary patient data were collected. The authors retrieved clinical studies, systematic reviews, meta-analyses, and experimental studies from PubMed and Scopus, focusing on the relationship between serum 25(OH)D levels, IBD disease activity, and vitamin D supplementation outcomes. No prospective follow-up period, randomization, or defined PICO protocol is described, which is typical for a narrative rather than systematic review format.

As a narrative review, the study is subject to selection bias in which literature is included and cannot generate pooled effect sizes or assess publication bias the way a formal meta-analysis would. The heterogeneity of included studies — differing IBD subtypes, disease activity indices, vitamin D assay methods, supplementation doses, and follow-up durations — makes it difficult to draw firm quantitative conclusions. The review cannot establish causality: it remains unclear whether vitamin D deficiency drives worse IBD outcomes or whether active intestinal inflammation reduces vitamin D absorption and synthesis. The next critical experiment would be a large, multi-center, double-blind RCT testing standardized vitamin D supplementation protocols stratified by IBD subtype, baseline 25(OH)D level, and disease activity to define optimal therapeutic targets.

This review directly extends [§150], which frames gut microbiota as a central hub for immune-related inflammatory diseases, by adding vitamin D as a parallel and potentially interacting axis of immune regulation in IBD. It parallels [§120], where Eubacterium rectale mitigates IBD through glutamine metabolism and NF-κB modulation, since both articles converge on intestinal barrier integrity and immune homeostasis as therapeutic targets, approached through different biological levers. The vitamin D–epithelial barrier relationship described here also complements [§144], which maps molecular pathways by which probiotics support intestinal barrier function, underscoring that multiple microenvironmental inputs — microbial and nutritional — cooperate to maintain mucosal integrity. Taken together, these articles suggest the corpus is building a multi-mechanistic picture of IBD in which no single pathway dominates, and combinatorial strategies (e.g., vitamin D plus probiotics or microbial metabolite-targeted therapies) deserve prospective evaluation.

• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  Directly complementary: this editorial reviews gut microbiota as an immune regulator in inflammatory diseases, making it an ideal parallel read to understand how vitamin D and microbial axes may interact in IBD.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Both converge on intestinal barrier integrity and immune modulation in IBD but via distinct mechanisms (microbial glutamine metabolism vs. vitamin D signaling), highlighting potentially additive therapeutic pathways.
• Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review
  Maps probiotic molecular pathways for intestinal barrier support, providing a mechanistic counterpart to vitamin D's epithelial tight-junction effects described in this review.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Focuses specifically on Saccharomyces boulardii and intestinal barrier function — a direct mechanistic comparator to vitamin D's barrier-maintenance role, in the same gut-disease context.
• Ulcerative colitis-driven gut dysbiosis exacerbates periodontal bone loss through the gut-oral axis /Th17/Treg imbalance
  Examines how ulcerative colitis-driven dysbiosis propagates systemic inflammation via Th17/Treg imbalance, a T-cell axis that vitamin D is reported to modulate, enabling cross-article comparison of immune-regulatory strategies.